Boult Wade Tennant
Bulletins » Enlarged Board of Appeal Issues Ruling in G 2/24

The Enlarged Board of Appeal (EBoA) of the EPO issued their ruling in case G 2/24 last week, confirming its earlier ruling in G 3/04 that a third party intervening at the appeal stage is a party as of right to proceedings, but does not acquire an appellant status corresponding to the status of a party entitled to appeal.

In this bulletin, we briefly examine the background to the case and the reasoning by which the EPO reached this decision.

Background
The background to the case was set out more fully by Boult partner Nigel Tucker, in this bulletin from December 2024.

Briefly, an opponent had appealed against a decision of the opposition division, which had maintained the granted patent as amended according to an auxiliary request of the patentee. In the meantime, a third-party had begun proceedings in the German courts, seeking a declaration of non-infringement of the granted patent.

The Enlarged Board of Appeal had previously ruled in G 3/04 that an assumed infringer intervening during appeal proceedings can be conferred the status of an opponent but not that of an appellant. This was based on the conclusion that the first sentence of Article 107 EPC required an appellant to have been a party to the proceedings leading to the decision: an assumed infringer could not meet this requirement as they intervened after the decision had been issued.  Consequently, such an assumed infringer could only become a party as of right within the sense of Article 107 EPC.

The key facts in the referring case for G 3/04 are broadly similar to the present referral, however the referring board had expressed their intention to deviate from this decision and criticised the earlier G 3/04 decision in its referral.

The Decision
The Enlarged Board broadly endorsed the previous decision of G 3/04 and found that an intervener who intervenes at the appeal stage is procedurally an accessory to the appeal proceedings initiated by one or more parties adversely affected by the decision under appeal. As such, the intervener does not acquire an appellant status corresponding to the status of a party entitled to appeal, but is instead a party as of right.

The implication of this is that if all appellants withdraw their respective appeals, the appeal proceedings cannot be continued with an intervener at appeal.

Reasons
In considering the admissibility of the referral, the Enlarged Board of Appeal made clear that they did not find the prospect of a point of Boards referring a question of law simply because they disagreed with an earlier Enlarged Board decision particularly appealing (see Reasons 9). However, the referral found support from a number of other sources, notably including the President of the EPO and the referral was found to be admissible.

In considering the referral, the EBoA first considered whether there had been any changes to the EPC since G 3/04 which would have a meaningful impact on the legal reasoning of the previous decision; this was potentially significant, since G 3/04 was based on the original EPC 1973, rather than the updated EPC 2000. However, the EBoA found that there were no substantive changes to any of the relevant Articles (specifically, Articles 99, 105 and 107 EPC).

Next, the Enlarged Board considered the legal concepts of appeal and intervention and their inter-relation and qualification as a party. With regard to the legal purpose of appeal, the Enlarged Board noted that (see Reasons 34), the appeal process at the European Patent Office (EPO) is not something that the EPO starts on its own to check or correct its own decisions, but rather the onus to initiate an appeal lies with the party who disagrees with a decision. Crucially, the Enlarged Board noted that the appellant is in control of the scope of the appeal with regard to which parts of the decision they want to challenge and whether to bring the appeal to an end, under the principle of party disposition. In considering Article 107 EPC, the Enlarged Board observed that this provision merely guarantees that parties to appeal proceedings as of right have a right to participate in pending appeal proceedings (Reasons 64).

Finally, the EBoA considered existing case law of the Boards of Appeal and a comparative analysis of different jurisdictions’ approaches to the status of interveners. The EBoA found two Board of Appeal cases in which the decision of G 3/04 had been followed and found no reason in the National laws of any of the EPC member states to deviate from the decision in G 3/04.

Consequently, the Enlarged Board ruled that proceedings cannot be continued by a third party at the appeal stage, where that third party only intervened at the appeal stage and the appellants have withdrawn the appeal.

See the full text of the ruling here.

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications
Relevant sectors